Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. WW
WW logo

WW Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
23.450
Open
22.690
VWAP
22.62
Vol
254.43K
Mkt Cap
223.51M
Low
22.040
Amount
5.76M
EV/EBITDA(TTM)
3.09
Total Shares
9.99M
EV
516.16M
EV/OCF(TTM)
--
P/S(TTM)
1.36
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
Show More

Events Timeline

(ET)
2026-03-11
07:50:00
Playboy Appoints Phillip Picardi as Chief Brand Officer
select
link
2026-02-10 (ET)
2026-02-10
09:10:00
WW International Forms Strategic Partnership with PVOLVE
select
2026-01-05 (ET)
2026-01-05
08:40:00
WW International Gains Access to Novo Nordisk's Wegovy Oral Drug
select
2025-12-16 (ET)
2025-12-16
09:10:00
WW International Launches New Integrated GLP-1 Experience Program
select
2025-11-17 (ET)
2025-11-17
08:23:28
Novo introduces a $199 monthly self-pay option for Wegovy and Ozempic.
select
2025-11-06 (ET)
2025-11-06
07:21:15
WW Announces Q3 Revenue of $172.091M, Down from $192.887M Last Year
select
2025-10-20 (ET)
2025-10-20
06:31:53
WW Partners with Amazon Pharmacy for New Collaboration
select

News

seekingalpha
7.5
03-11seekingalpha
Weight Watchers' GLP-1 Program Shows Significant Weight Loss Benefits
  • Significant Weight Loss: Weight Watchers' GLP-1 Success Program, when combined with weight loss medications, resulted in participants losing up to 61% more weight in the first month and 29% more over a year compared to those using medications alone, highlighting the program's effectiveness.
  • Improved Health Outcomes: CEO Tara Comonte emphasized that while GLP-1 medications are crucial in obesity treatment, they alone cannot ensure lasting results; integrating Weight Watchers' support fosters better health habits and outcomes.
  • Platform Benefits: The Med+ platform offers FDA-approved weight loss medications, access to physicians, and lifestyle support, aimed at helping users establish sustainable habits and mitigate side effects from GLP-1s, thereby enhancing overall weight loss effectiveness.
  • Market Challenges: Despite Weight Watchers' efforts to capitalize on the GLP-1 trend, the stock has declined by 51% since emerging from bankruptcy, indicating significant challenges in the market and the need to validate the long-term effectiveness of its weight loss programs.
Newsfilter
7.5
02-10Newsfilter
Weight Watchers Partners with PVOLVE for Enhanced Weight Health Solutions
  • Strategic Partnership: Weight Watchers has formed a strategic partnership with PVOLVE to introduce a clinically validated workout method aimed at supporting long-term health through enhanced strength, mobility, and stability, particularly for midlife women and members using GLP-1 medications.
  • Expanded Member Benefits: Weight Watchers members will gain access to exclusive PVOLVE classes suitable for all fitness levels and life stages, and they can also access PVOLVE's full on-demand library through Weight Watchers and purchase a curated starter kit, enhancing their workout experience.
  • Data-Driven Results: Data from the Weight Watchers Med+ program shows that participants lost 61.3% more body weight than those using medication alone within one month, and 29.1% more at twelve months, demonstrating the effectiveness of the integrated approach.
  • Setting Industry Standards: By partnering with PVOLVE, Weight Watchers further integrates medical care, nutrition, behavior change, and movement, setting industry standards and emphasizing the importance of strength and muscle preservation in lasting weight health.
Benzinga
8.5
02-09Benzinga
Valaris Shares Surge 21.8% Amid Transocean Acquisition Deal
  • Significant Price Surge: Valaris shares jumped 21.8% to $76.02 on Monday, reflecting strong market confidence in the company's upcoming acquisition by Transocean, indicating a positive investor sentiment towards the deal.
  • Clear Transaction Terms: Under the terms of the all-stock transaction, Valaris shareholders will receive 15.235 shares of Transocean stock for each Valaris share, which may attract more investor interest in Valaris's future performance.
  • Mixed Market Performance: U.S. stocks were mixed on Monday, with the Nasdaq gaining around 100 points, showcasing strong performance in tech stocks amidst volatility in other sectors, reflecting the complexity of market sentiment.
  • Investor Focus: The acquisition news surrounding Valaris has sparked widespread market attention, potentially influencing the stock prices of other related companies, prompting investors to closely monitor subsequent market reactions and industry developments.
Fool
8.5
02-06Fool
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
  • Intensifying Market Competition: Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the GLP-1 drug space, particularly as Novo Nordisk is set to regain market share by launching the oral version of Wegovy in 2026, which could shift overall market dynamics.
  • Amazon's Market Opportunity: Amazon has begun selling the oral version of Wegovy, with monthly costs as low as $25 for insured customers and $149 for uninsured ones, positioning itself to capture significant retail market share due to its vast customer base and convenient purchasing options.
  • Shifting Consumer Preferences: The introduction of oral GLP-1 drugs is expected to encourage more consumers to try these medications for weight loss, driving overall demand and benefiting all companies involved in this sector.
  • Impact on Competitive Landscape: Companies like Hims & Hers, WW International, and GoodRx face tough competition, especially as GLP-1 drugs gain popularity; Amazon's 200 million Prime members provide it with a substantial advantage in the e-commerce space, potentially leading to a decline in market share for other competitors.
Benzinga
8.5
01-23Benzinga
Novo Nordisk's Oral Wegovy Hits Record 20,371 Prescriptions in Second Week, Nearly 500% Surge
  • Prescription Surge: Novo Nordisk's oral Wegovy reached 20,371 prescriptions in its second week, a nearly 500% increase from 4,289 in the first week, indicating rapid market acceptance that could reshape revenue trajectories in the weight-loss drug market.
  • Significant Market Potential: This figure is likely conservative as retail prescription data excludes Novo Nordisk's direct-to-consumer channels and telehealth platforms, suggesting actual demand could be double or triple the reported number, indicating a larger market opportunity.
  • Clear Competitive Advantage: With distribution in over 70,000 retail locations, Novo Nordisk has established brand loyalty before Eli Lilly's oral competitor, Orforglipron, is set to launch in 2026, giving Novo a significant first-mover advantage.
  • Industry Transformation Signal: The mainstream adoption of oral GLP-1 drugs could dramatically expand the total addressable market for weight-loss medications, altering revenue trajectories for both Novo and Lilly, with increasing market attention suggesting Wall Street may be underestimating the potential explosion in this sector.
Newsfilter
7.5
01-09Newsfilter
Amazon Launches Novo Nordisk's Wegovy Weight-Loss Pill with Monthly Costs Starting at $25
  • Drug Launch: Amazon has introduced Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy, with cash-paying patients facing a monthly cost starting at $149, while insured patients can access it for as low as $25, significantly lowering the barrier to obesity medication access and likely attracting more consumers.
  • Market Expansion: The launch of the Wegovy pill marks Novo Nordisk's first oral GLP-1 drug release in the U.S., aiming to disrupt the dominance of traditional injectable medications and further expand its customer base while increasing market share.
  • Strategic Partnerships: Since its launch in 2020, Amazon Pharmacy has collaborated with companies like WeightWatchers and Eli Lilly to deliver weight-loss medications, with analysts estimating annual revenue could reach $2 billion, thereby solidifying its position in the U.S. healthcare sector.
  • Convenient Services: Amazon promises same-day prescription delivery for nearly half of U.S. consumers, and this strategy of rapid delivery and price transparency is expected to enhance user experience and attract more users to its pharmacy services.
Wall Street analysts forecast WW stock price to rise
1 Analyst Rating
Wall Street analysts forecast WW stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
38.00
Averages
38.00
High
38.00
Current: 0.000
sliders
Low
38.00
Averages
38.00
High
38.00
Morgan Stanley
Equal Weight
downgrade
$41 -> $38
AI Analysis
2025-11-07
Reason
Morgan Stanley
Price Target
$41 -> $38
AI Analysis
2025-11-07
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on WW to $38 from $41 and keeps an Equal Weight rating on the shares.
CJS Securities
initiated
$44
2025-09-15
Reason
CJS Securities
Price Target
$44
2025-09-15
initiated
Reason
CJS Securities initiated coverage of WW with a Market Perform rating and $44 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WW
Unlock Now

Valuation Metrics

The current forward P/E ratio for WW International Inc (WW.O) is 20.03, compared to its 5-year average forward P/E of -15.78. For a more detailed relative valuation and DCF analysis to assess WW International Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.78
Current PE
20.03
Overvalued PE
138.01
Undervalued PE
-169.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.32
Current EV/EBITDA
5.98
Overvalued EV/EBITDA
15.07
Undervalued EV/EBITDA
7.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.60
Current PS
0.50
Overvalued PS
1.18
Undervalued PS
0.02

Financials

AI Analysis
Annual
Quarterly

Whales Holding WW

C
Cooper Creek Partners Management LLC
Holding
WW
+12.30%
3M Return
C
Contrarius Investment Management Ltd.
Holding
WW
+3.85%
3M Return
A
Aristeia Capital, LLC
Holding
WW
-0.36%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is WW International Inc (WW) stock price today?

The current price of WW is 22.38 USD — it has increased 1.22

What is WW International Inc (WW)'s business?

WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.

What is the price predicton of WW Stock?

Wall Street analysts forecast WW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WW is38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is WW International Inc (WW)'s revenue for the last quarter?

WW International Inc revenue for the last quarter amounts to 172.09M USD, decreased -10.78

What is WW International Inc (WW)'s earnings per share (EPS) for the last quarter?

WW International Inc. EPS for the last quarter amounts to -5.76 USD, increased 893.10

How many employees does WW International Inc (WW). have?

WW International Inc (WW) has 3700 emplpoyees as of March 12 2026.

What is WW International Inc (WW) market cap?

Today WW has the market capitalization of 223.51M USD.